NASDAQ: LPCN
Lipocine Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their LPCN stock forecasts and price targets.

Forecast return on equity

Is LPCN forecast to generate an efficient return?

Company
-23.95%
Industry
117.29%
Market
45.6%
LPCN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LPCN forecast to generate an efficient return on assets?

Company
-22.34%
Industry
89.77%
LPCN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LPCN earnings per share forecast

What is LPCN's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.94

LPCN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LPCN$3.26N/AN/A
UBX$1.01$4.00+296.04%Strong Buy
BCTX$4.59$32.00+597.17%Buy
EDSA$2.37$21.00+786.08%Buy
COCP$1.61$7.00+336.14%Buy

Lipocine Stock Forecast FAQ

What is LPCN's earnings growth forecast for 2025-2025?

(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Lipocine's earnings in 2025 is $8,352.

In 2025, LPCN is forecast to generate -$5,029,335 in earnings, with the lowest earnings forecast at -$5,029,335 and the highest earnings forecast at -$5,029,335.

If you're new to stock investing, here's how to buy Lipocine stock.

What is LPCN's forecast return on equity (ROE) for 2025-2025?

(NASDAQ: LPCN) forecast ROE is -23.95%, which is considered weak.

What is LPCN's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: LPCN) Lipocine's current Earnings Per Share (EPS) is $0.00. In 2025, LPCN's EPS is forecast to hit -$0.94 (min: -$0.94, max: -$0.94).

What is LPCN's forecast return on assets (ROA) for 2025-2025?

(NASDAQ: LPCN) forecast ROA is -22.34%, which is lower than the forecast US Biotechnology industry average of 89.77%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.